`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`
`
`C. A. No. 20-1524-LPS
`
`
`
`
`
`
` )
`
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`Plaintiffs,
`
`Defendant.
`
`
`DAIICHI SANKYO, INC., DAIICHI SANKYO
`COMPANY, LIMITED, and ASTRAZENECA
`PHARMACEUTICALS LP
`
`
`
`v.
`
`SEAGEN INC.,
`
`
`
`
`
`
`
`
`
`
`
`PLAINTIFFS’ NOTICE OF SECOND POST-GRANT REVIEW PETITION
`
`
`
`Plaintiffs Daiichi Sankyo, Inc. (“Daiichi Sankyo US”), Daiichi Sankyo Company, Limited
`
`(“Daiichi Sankyo Japan”), and AstraZeneca Pharmaceuticals, LP (“AstraZeneca US”) notify the
`
`Court that on January 22, 2021, Daiichi Sankyo US and AstraZeneca US filed a Petition for Post-
`
`Grant Review seeking cancelation of Claims 6–8 of Defendant Seagen Inc.’s U.S. Patent No.
`
`10,808,039 (the “’039 Patent”), the sole patent at issue in this declaratory judgment action. Daiichi
`
`Sankyo US and AstraZeneca US previously filed a Petition for Post-Grant Review seeking
`
`cancelation of Claims 1–5, 9, and 10 of the ’039 Patent on December 23, 2020. (See D.I. 14.) All
`
`claims of the ’039 Patent are now subject to a pending petition for post-grant review. While
`
`Daiichi Sankyo Japan is not a party to either Petition, Daiichi Sankyo Japan is a real party-in-
`
`interest to both Petitions. Daiichi Sankyo US is a Delaware corporation and subsidiary of Daiichi
`
`Sankyo Japan. It is the only company licensed by the United States Food and Drug Administration
`
`to sell Enhertu®, the product at issue in this action. AstraZeneca US co-markets Enhertu® with
`
`Daiichi Sankyo US. The Patent Trial and Appeal Board will decide whether to institute post-grant
`
`review of Claims 1–5, 9, and 10 of the ’039 Patent by July 26, 2021.
`
`
`
`{01655963;v1 }
`
`
`
`
`
`Case 1:20-cv-01524-LPS Document 22 Filed 01/26/21 Page 2 of 2 PageID #: 556
`
`
`
`
`
`
`
`
`Of Counsel:
`
`Preston K. Ratliff II
`Joseph M. O’Malley, Jr.
`Ashley N. Mays-Williams
`Paul Hastings LLP
`200 Park Avenue
`New York, NY 10166
`(212) 318-6000
`
`Naveen Modi
`Michael A. Stramiello
`Paul Hastings LLP
`2050 M Street NW
`Washington, D.C. 20036
`(202) 551-1700
`
`
`
`
`
`
`
`Of Counsel:
`
`David I. Berl
`Thomas S. Fletcher
`Williams & Connolly LLP
`725 Twelfth St. NW
`Washington, DC 20005
`(202) 434-5000
`
`Dated: January 26, 2021
`
`{01655963;v1 }
`
`
`ASHBY & GEDDES
`
`/s/ Steven J. Balick
`Steven J. Balick (#2114)
`Andrew C. Mayo (#5207)
`500 Delaware Avenue, 8th Floor
`P.O. Box 1150
`Wilmington, DE 19899
`(302) 654-1888
`sbalick@ashbygeddes.com
`amayo@ashbygeddes.com
`
`Attorneys for Plaintiffs Daiichi Sankyo, Inc.
`and Daiichi Sankyo Company, Limited
`
`
`MCCARTER & ENGLISH, LLP
`
`/s/ Daniel M. Silver
`Michael P. Kelly (# 2295)
`Daniel M. Silver (#4758)
`Renaissance Centre
`405 N. King Street, 8th Floor
`Wilmington, Delaware 19801
`Tel.: (302) 984-6300
`Fax: (302) 984-6399
`mkelly@mccarter.com
`dsilver@mccarter.com
`
`Attorneys for Plaintiff AstraZeneca
`Pharmaceuticals LP
`
`
`
`
`
`- 2 -
`
`